GALNT14 SNP as a potential predictor of response to combination chemotherapy using 5-FU, mitoxantrone and cisplatin in advanced HCC

Pharmacogenomics

Volumn 12, Issue 7, 2011, Pages 1061-1073

  Liang, Kung Hao ^a   Lin, Chen Chun ^a   Yeh, Chau Ting ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

chemotherapy; FMP; GALNT14; glycosyltransferase; hepatocellular carcinoma

Indexed keywords

CISPLATIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; MITOXANTRONE;

ADULT; ADVANCED CANCER; ALLELE; ANEMIA; ARTICLE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHROMOSOME 2; COHORT ANALYSIS; CONTINUOUS INFUSION; DIARRHEA; DOMINANT INHERITANCE; DRUG RESPONSE; FATIGUE; FEMALE; GALNT14 GENE; GENE; GENE LINKAGE DISEQUILIBRIUM; GENETIC SCREENING; GENOTYPE; HOMOZYGOSITY; HUMAN; INFECTION; INTRON; KIDNEY FAILURE; LEUKOPENIA; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RECESSIVE INHERITANCE; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, PHARMACOLOGICAL; CARCINOMA, HEPATOCELLULAR; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LINKAGE DISEQUILIBRIUM; LIVER NEOPLASMS; MALE; MIDDLE AGED; MITOXANTRONE; N-ACETYLGALACTOSAMINYLTRANSFERASES; NEOPLASM STAGING; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES;

EID: 79960757676     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.11.43     Document Type: Article

References (28)

1. Llovet JM, Ricci S, Mazzaferro V et al.: Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378-390 (2008).
2. Cheng AL, Kang Y, Chen Z et al.: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a Phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10, 25-34 (2009).
3. Johnson PJ, Williams R, Thomas H, Sherlock S, Murray-Lyon IM: Induction of remission in hepatocellular carcinoma with doxorubicin. Lancet 1, 1006-1009 (1978). (Pubitemid 8342858)
4. Ikeda M, Okusaka T, Ueno H, Takezako Y, Morizane C: A Phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma. Cancer 103, 756-762 (2005). (Pubitemid 40216404)
5. Yang TS, Chang HK, Chen JS, Lin YC, Liau CT, Chang WC: Chemotherapy using 5-fluorouracil, mitoxantrone, and cisplatin for patients with advanced hepatocellular carcinoma: an analysis of 63 cases. J. Gastroenterol. 39, 362-369 (2004).
6. Lee W, Lockhart AC, Kim RB, Rothenberg ML: Cancer pharmacogenomics: powerful tools in cancer chemotherapy and drug development. Oncologist 10, 104-111 (2005). (Pubitemid 40261949)
7. Evans WE, McLeod HL: Pharmacogenomics-drug disposition, drug targets, and side effects. N. Engl. J. Med. 348, 538-549 (2003). (Pubitemid 36159890)
8. Shirota Y, Stoehlmacher J, Brabender J et al.: ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J. Clin. Oncol. 19, 4298-4304 (2001). (Pubitemid 33096777)
9. Lord RV, Brabender J, Gandara D et al.: Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin. Cancer Res. 8, 2286-2291 (2002). (Pubitemid 34753602)
10. Zhou W, Gurubhagavatula S, Liu G et al.: Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small-cell lung cancer patients treated with platinum based chemotherapy. Clin. Cancer Res. 10, 4939-4943 (2004). (Pubitemid 39099767)
11. Kamikozuru H, Kuramochi H, Hayashi K, Nakajima G, Yamamoto M: ERCC1 codon 118 polymorphism is a useful prognostic marker in patients with pancreatic cancer treated with platinum-based chemotherapy. Int. J. Oncol. 32, 1091-1096 (2008).
12. Uchida K, Hayashi K, Kawakami K et al.: Loss of heterozygosity at the thymidylate synthase (TS) locus on chromosome 18 affects tumor response and survival in individuals heterozygous for a 28-bp polymorphism in the TS gene. Clin. Cancer Res. 10, 4333-4339 (2004).
13. Gomez HL, Santillana SL, Vallejos CS et al.: A Phase II trial of pemetrexed in advanced breast cancer: clinical response and association with molecular target expression. Clin. Cancer Res. 12, 832-838 (2006). (Pubitemid 43259865)
14. Viguier J, Boige V, Miquel C et al.: ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer. Clin. Cancer Res. 11, 6212-6217 (2005). (Pubitemid 41262950)
15. Kurokawa Y, Matoba R, Nagano H et al.: Molecular prediction of response to 5-fluorouracil and interferon-a combination chemotherapy in advanced hepatocellular carcinoma. Clin. Cancer Res. 10, 6029-6038 (2004). (Pubitemid 39287507)
16. Iyer L, Das S, Janisch L et al.: UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2, 43-47 (2002). (Pubitemid 34982202)
17. Eisenhauer EA, Therasse P, Bogaerts J et al.: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) European J. Cancer 45, 228-247 (2009).
18. Hong H, Su Z, Ge W et al.: Assessing batch effects of genotype calling algorithm BRLMM for the Affymetrix GeneChip Human Mapping 500 K array set using 270 HapMap samples. BMC Bioinformatics 9(Suppl. 9), S17 (2008).
19. Minelli C, Thompson JR, Abrams KR et al.: How should we use information about HWE in the meta-analysis of genetic association studies? Int. J. Epidemiol. 37, 136-146 (2008). (Pubitemid 351228622)
20. Clayton D: Testing for association on the X chromosome. Biostatistics 9, 593-600 (2008).
21. Zaykin, D: Zhivotovsky VLA, Westfall PH, Weir BS: Truncated product method for combining p values. Genet. Epidemiol. 22, 170-185 (2002). (Pubitemid 34081490)
22. Yang HC, Hsieh HY, Fann CSJ: Kernel-based association test. Genetics 179, 1057-1068 (2008).
23. Wellcome Trust Case Control Consortium: Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447, 661-678 (2007).
24. Kleinbaum DG, Klein M: Survival Analysis: A Self-Learning Text. Springer Science+Business Media Inc., NY, USA (2005).
25. Hirschhorn JN, Daly MJ: Genome-wide association studies for common diseases and complex traits. Nat. Rev. Genet. 6, 95-108 (2005). (Pubitemid 40179532)
26. Wagner KW, Punnoose EA, Januario T et al.: Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat. Med. 13, 1070-1077 (2007). (Pubitemid 47517508)
27. Wu C, Guo X, Wang W et al.: N-acetylgalactosaminyltransferase-14 as a potential biomarker for breast cancer by immunohistochemistry. BMC Cancer 10, 123 (2010).
28. Wang H, Tachibana K, Zhang Y et al.: Cloning and characterization of a novel UDP-GalNAc: polypeptide N-acetylgalactosaminyltransferase, pp-GalNAc-T14. Biochem. Biophys. Res. Commun. 17, 738-744 (2003). (Pubitemid 36268899)